New drug cocktail aims to boost lymphoma treatment
NCT ID NCT04978584
First seen Nov 01, 2025 · Last updated Jun 12, 2026 · Updated 30 times
Summary
This study tests whether giving a mix of targeted drugs (rituximab, lenalidomide, acalabrutinib, tafasitamab) before and with standard chemotherapy can better control a fast-growing lymphoma called DLBCL. About 62 adults with newly diagnosed disease will take part. The goal is to see if this approach improves response rates while keeping side effects manageable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.